Sanofi Shares Drop 2.57% at Close Despite 1 Billion Euro Investment in France
The stock of the French pharmaceutical giant closed sharply lower this Tuesday, November 18, significantly underperforming the CAC 40. The decline occurred in an unfavorable market context, despite the announcement of an ambitious investment plan in France the day before.
Session Overview
Sanofi's stock ended the session at 87.58 euros, down 2.57% from Monday's close of 89.89 euros. This decline was more pronounced than that of the CAC 40, which lost 1.86% to 7,967.93 points. Trading volumes remained modest, with 0.21% of the capital traded during the day. Over a broader horizon, the stock still shows relative resilience: it has gained 0.89% over the past week and 3.1% over three months. However, its one-year performance remains negative with a decline of 4.09%, significantly lagging behind the CAC 40, which advanced 9.61% over the same period. The stock is now fluctuating between a technical support identified at 83.34 euros and a resistance at 90.44 euros. The session followed a significant announcement: on November 17, during the Choose France summit, Sanofi unveiled an investment plan of 1 billion euros in France for 2025-2026, with 700 million dedicated to the modernization of its industrial tools and 300 million allocated to artificial intelligence. These amounts are in addition to the 2.5 billion euros invested annually in R&D in France, making the group the leading private investor in research across all sectors in the country. However, this strategic communication was not enough to support the stock price in a deteriorated market context on Tuesday.
Technical Analysis
Technically, the MACD remains positive but is still below its signal line, suggesting a disruption in the ongoing momentum. The indicator shows a value of 1.43 against 1.29 for the signal line, with a positive histogram of 0.14 indicating a weakening of the bullish trend. The RSI is at 63, a level that still reflects some strength without indicating an overbought zone. The stock is now trading above its 50-day moving average, set at 84.35 euros, but remains below its 200-day moving average of 89.79 euros. This gap of more than 2 euros between the current price and this long-term average illustrates the difficulty of the stock in regaining its fundamental trend. The Bollinger Bands, ranging from 84.53 to 90.75 euros, frame the current price which is located in the upper half of this channel, indicating contained volatility in the short term. Additionally, the stock displays a particularly low beta of 0.20, reflecting its defensive nature and low sensitivity to market movements. A modest buy signal is noted: a transaction by a director was recorded with the purchase of 207 shares for approximately 16,371 euros, potentially a sign of internal confidence.
Market Context and Future Outlook
Since February 2025, Sanofi's stock has been engaged in a downward trend after a significant correction of more than 22% between March and April 2025, since then fluctuating around several key technical levels. The third quarter 2025 results, published on October 24, were solid with revenue of 12.43 billion euros, up 7% at constant exchange rates. The flagship drug Dupixent surpassed the 4 billion euro sales mark for the first time in a quarter, with a 26.2% increase. The group maintains its 2025 targets with expected revenue growth between 7 and 9% and a double-digit increase in earnings per share. Despite these encouraging fundamentals, the stock struggles to convince investors in a market environment marked by risk aversion.
